Skip to site menu Skip to page content

Daily Newsletter

Daily Newsletter

NVIDIA-backed Charm secures $80m to advance AML drug

Charm’s molecule is designed to overcome the safety and long-term efficacy issues impacting first-generation menin inhibitors such as Syndax’s Revuforj.

Annabel Kartal Allen September 02 2025

UK biotech Charm Therapeutics has raised $80m in a Series B funding round, which will be used to progress its menin inhibitor to Phase I clinical trials for AML. Image credit: Nemes Laszlo via ShutterStock.com.

Unlock FREE Access to Premium Content

​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends.

With a free Pharmaceutical Technology profile, you can:

  • Access exclusive analyst commentary and expert insights
  • View premium forecasts and data-driven pharmaceutical industry insights
  • Stay up to date with pharma news, manufacturing innovation, and regulatory developments
  • Receive alerts when new premium content is published
Unlock free access
Already have an account? Login here

Powered by

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Browse reports

Newsletters by sectors

Clinical Trials Arena open-new-tab

Medical Device Network open-new-tab

Hospital Management open-new-tab

View more newsletters

Sign up to the newsletter

 

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close